Shunsuke Kiuchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shunsuke Kiuchi has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Takanori Ikeda
18 shared publicationsShinji Hisatake
12 shared publicationsTakayuki Kabuki
Department of Cardiovascular Medicine Toho University Faculty of Medicine Tokyo Japan
11 shared publicationsShintaro Dobashi
Department of Cardiovascular Medicine Toho University Faculty of Medicine Tokyo Japan
10 shared publicationsTakashi Oka
Department of Cardiovascular Medicine, Toho University Graduate School of Medicine, Tokyo, Japan
8 shared publicationsTakahiro Fujii
Department of Cardiovascular Medicine, Toho University Graduate School of Medicine, Tokyo, Japan
7 shared publications
Latest Publications
- Open Access
The Evaluation of Relative Left Ventricular Wall Thickness on Echocardiography for the Diagnosis of ATTR Cardiac Amyloidosis
Background: The number of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) has been increasing recently, and the early diagnosis and treatment of it are important. 99mTc pyrophosphate scintigraphy (99mTc-PYP) plays a key role in the early diagnosis of ATTR-CM. In patients who underwent 99mTc-PYP, the early diagnosis of ATTR-CM by echocardiography was evaluated, focusing on left ventricular myocardial form and left ventricular wall thickness. Methods: The present study was conducted on 144 patients who underwent 99mTc-PYP between February 2020 and March 2024. A comparison was made between the 99mTc-PYP positive (P) and negative (N) groups, and significant factors were subjected to multivariate analysis. Results: 17 of 144 patients were positive (14.9%), and 15 patients were diagnosed with ATTR-CM by myocardial or skin (fat) biopsy. Other positive patients were also clinically considered to have ATTR-CM based on findings such as poor cardiac function and cerebral hemorrhage. 99mTc-PYP positive had a significantly larger CTR (60.3% in the P group vs. 53.9% in the N group, p = 0.007) and a larger left atrial diameter (42.8 mm in the P group vs. 40.0 mm in the N group, p = 0.047). On the other hand, the mean LV wall thickness was significantly thicker (15.7 mm in the P group vs. 12.8 mm in the N group, p < 0.001); however the LV end-diastolic diameter was smaller (41.9 mm in the P group vs. 48.4 mm in the P group, p < 0.001). The LV mass was similar in both groups, thus the relative left ventricular wall thickness (RWT), which indicates relative wall thickening, was significantly higher in the P group (0.85 in the P group vs. 0.52 mm in the N group, p < 0.001). The receiver operating characteristic curve of RWT for assessing 99mTc-PYP positivity had a cut-off value of 0.717 (area under the curve 0.862, 95%CI 0.763–0.961). Conclusions: The evaluation of wall thickness and RWT on echocardiography is important for diagnosing ATTR-CM.
Open AccessThe Evaluation of Relative Left Ventricular Wall Thickness on Echocardiography for the Diagnosis of ATTR Cardiac Amyloidosis
Background: The number of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) has been increasing recently, and the early diagnosis and treatment of it are important. 99mTc pyrophosphate scintigraphy (99mTc-PYP) plays a key role in the early diagnosis of ATTR-CM. In patients who underwent 99mTc-PYP, the early diagnosis of ATTR-CM by echocardiography was evaluated, focusing on left ventricular myocardial form and left ventricular wall thickness. Methods: The present study was conducted on 144 patients who underwent 99mTc-PYP between February 2020 and March 2024. A comparison was made between the 99mTc-PYP positive (P) and negative (N) groups, and significant factors were subjected to multivariate analysis. Results: 17 of 144 patients were positive (14.9%), and 15 patients were diagnosed with ATTR-CM by myocardial or skin (fat) biopsy. Other positive patients were also clinically considered to have ATTR-CM based on findings such as poor cardiac function and cerebral hemorrhage. 99mTc-PYP positive had a significantly larger CTR (60.3% in the P group vs. 53.9% in the N group, p = 0.007) and a larger left atrial diameter (42.8 mm in the P group vs. 40.0 mm in the N group, p = 0.047). On the other hand, the mean LV wall thickness was significantly thicker (15.7 mm in the P group vs. 12.8 mm in the N group, p < 0.001); however the LV end-diastolic diameter was smaller (41.9 mm in the P group vs. 48.4 mm in the P group, p < 0.001). The LV mass was similar in both groups, thus the relative left ventricular wall thickness (RWT), which indicates relative wall thickening, was significantly higher in the P group (0.85 in the P group vs. 0.52 mm in the N group, p < 0.001). The receiver operating characteristic curve of RWT for assessing 99mTc-PYP positivity had a cut-off value of 0.717 (area under the curve 0.862, 95%CI 0.763–0.961). Conclusions: The evaluation of wall thickness and RWT on echocardiography is important for diagnosing ATTR-CM.
- Open Access
- 24 December 2025
- Published by MDPI AG in Diagnostics
- Vol. 16 (1) , 65
Electrocardiographic Features in Transthyretin Cardiac Amyloidosis
Background: 99mTc pyrophosphate scintigraphy (99mTc-PYP) is useful for diagnosing transthyretin amyloid cardiomyopathy (ATTR-CA). We examined the characteristics of 99mTc-PYP-positive patients at our institution. Methods: A total of 76 patients who underwent 99mTc-PYP from December 2020 and March 2022 were grouped into 99mTc-PYP-positive (P) and -negative (N) groups and compared. Results: Nine of seventy-six patients were positive (11.8%), and all patients were diagnosed with ATTR-CA by myocardial biopsy or clinical findings. The heart-to-contralateral lung ratio in the P group was significantly higher (N Group: 1.15, P Group: 1.92, p < 0.001). In the P group, the left ventricular posterior wall thickness was significantly thickened (N Group; 12.5 mm, P Group; 15.5 mm, p = 0.003). Electrocardiogram showed left ventricular hypertrophy (LVH) was observed more frequently in the N group (N Group; 30 patients (44.8%) and the P Group; 1 patient (11.1%), p < 0.001). In addition, the QTc interval was significantly prolonged in the P group (N Group; 422 msec, P Group; 456 msec, p = 0.001). Conclusions: In patients who have significant LVH on echocardiogram but not on electrocardiogram, 99mTc-PYP may be useful for diagnosing ATTR-CA. However, the present study is a single-center retrospective study with a small number of patients, and the results are exploratory and hypothesis-generating. Prospective studies with a larger number of subjects are needed.
- 24 December 2025
- Published by MDPI AG in Diagnostics
- Vol. 16 (1) , 65
Open AccessElectrocardiographic Features in Transthyretin Cardiac Amyloidosis
Background: 99mTc pyrophosphate scintigraphy (99mTc-PYP) is useful for diagnosing transthyretin amyloid cardiomyopathy (ATTR-CA). We examined the characteristics of 99mTc-PYP-positive patients at our institution. Methods: A total of 76 patients who underwent 99mTc-PYP from December 2020 and March 2022 were grouped into 99mTc-PYP-positive (P) and -negative (N) groups and compared. Results: Nine of seventy-six patients were positive (11.8%), and all patients were diagnosed with ATTR-CA by myocardial biopsy or clinical findings. The heart-to-contralateral lung ratio in the P group was significantly higher (N Group: 1.15, P Group: 1.92, p < 0.001). In the P group, the left ventricular posterior wall thickness was significantly thickened (N Group; 12.5 mm, P Group; 15.5 mm, p = 0.003). Electrocardiogram showed left ventricular hypertrophy (LVH) was observed more frequently in the N group (N Group; 30 patients (44.8%) and the P Group; 1 patient (11.1%), p < 0.001). In addition, the QTc interval was significantly prolonged in the P group (N Group; 422 msec, P Group; 456 msec, p = 0.001). Conclusions: In patients who have significant LVH on echocardiogram but not on electrocardiogram, 99mTc-PYP may be useful for diagnosing ATTR-CA. However, the present study is a single-center retrospective study with a small number of patients, and the results are exploratory and hypothesis-generating. Prospective studies with a larger number of subjects are needed.
- Open Access
- 20 March 2025
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (3) , 107
Comprehensive Self-Management of Heart Failure
In response to the heart failure (HF) pandemic, it is important to introduce appropriate pharmacological and non-pharmacological treatments for HF patients. In addition, self-management of HF, including the continuation of appropriate pharmacological treatment, is also important. There have been many reports on self-management of HF. However, the effectiveness of patient education of HF is not consistent. One of the reasons may be whether the tools used are common or not. Moreover, unified systems of HF patient education and disease management in metropolitan areas are rare. We began joint HF patient education and disease management in the Tokyo southern medical district (JONAN Heart Failure Medical Collaboration: JHFeC). Patients undergo a multidisciplinary HF education program at JHFeC member hospitals to ensure that they are able to adequately record information on the self-management sheet. After discharge, the continuity of self-management will be evaluated, and further education will be provided if necessary. HF patient education is important even in severe HF requiring a left ventricular assist device, and such patient education needs to be provided appropriately in all manner of HF patients with stage A to D.
- 20 March 2025
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (3) , 107
Open AccessComprehensive Self-Management of Heart Failure
In response to the heart failure (HF) pandemic, it is important to introduce appropriate pharmacological and non-pharmacological treatments for HF patients. In addition, self-management of HF, including the continuation of appropriate pharmacological treatment, is also important. There have been many reports on self-management of HF. However, the effectiveness of patient education of HF is not consistent. One of the reasons may be whether the tools used are common or not. Moreover, unified systems of HF patient education and disease management in metropolitan areas are rare. We began joint HF patient education and disease management in the Tokyo southern medical district (JONAN Heart Failure Medical Collaboration: JHFeC). Patients undergo a multidisciplinary HF education program at JHFeC member hospitals to ensure that they are able to adequately record information on the self-management sheet. After discharge, the continuity of self-management will be evaluated, and further education will be provided if necessary. HF patient education is important even in severe HF requiring a left ventricular assist device, and such patient education needs to be provided appropriately in all manner of HF patients with stage A to D.
- Open Access
- 3 March 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (3) , 99
Combination of SGLT2 Inhibitors and Loop Diuretics in the Treatment of Heart Failure
Background: Administration of SGLT2 inhibitors leads to a reduction in the dosage of loop diuretics in heart failure (HF) patients; however, it is unclear in what patients the dosage can be reduced. We investigated the factors related to the reduction in loop diuretics in patients who have started receiving dapagliflozin, an SGLT2 inhibitor. Methods: In total, 126 consecutive patients with HF who received dapagliflozin for HF at our institution between December 2020 and March 2022 were enrolled. We investigated the change in the dosage of diuretics at the time of dapagliflozin administration and after 6 months and evaluated factors at the time of dapagliflozin initiation that were associated with the dosage of loop diuretic reduction. Results: The median of loop diuretics dosage (oral furosemide equivalent) at the time of dapagliflozin administration was 20 mg/day (the mean dosage; 29.5 ± 26.5 mg/day), and after 6 months it decreased to 10 mg/day (the mean dosage; 14.5 ± 15.9 mg/day) (p < 0.001). Multivariate analysis showed that the three factors of in-hospital start of dapagliflozin, % patients on β-blockers, and the dosage of loop diuretics independently predicted the reduction in loop diuretic dosage. Even in analyses excluding patients who initiated dapagliflozin during hospitalization, loop diuretic dosage independently predicted loop diuretic reduction in multivariate analysis. The receiver operating characteristic curve for predicting reduced loop diuretic showed that the cut-off value for loop diuretic at the time of administration of dapagliflozin was 20 mg/day of oral furosemide equivalent. Conclusions: The dosage of loop diuretic used when dapagliflozin was started is a factor that predicts a subsequent reduction in the dose of loop diuretics.
- 3 March 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (3) , 99
Open AccessCombination of SGLT2 Inhibitors and Loop Diuretics in the Treatment of Heart Failure
Background: Administration of SGLT2 inhibitors leads to a reduction in the dosage of loop diuretics in heart failure (HF) patients; however, it is unclear in what patients the dosage can be reduced. We investigated the factors related to the reduction in loop diuretics in patients who have started receiving dapagliflozin, an SGLT2 inhibitor. Methods: In total, 126 consecutive patients with HF who received dapagliflozin for HF at our institution between December 2020 and March 2022 were enrolled. We investigated the change in the dosage of diuretics at the time of dapagliflozin administration and after 6 months and evaluated factors at the time of dapagliflozin initiation that were associated with the dosage of loop diuretic reduction. Results: The median of loop diuretics dosage (oral furosemide equivalent) at the time of dapagliflozin administration was 20 mg/day (the mean dosage; 29.5 ± 26.5 mg/day), and after 6 months it decreased to 10 mg/day (the mean dosage; 14.5 ± 15.9 mg/day) (p < 0.001). Multivariate analysis showed that the three factors of in-hospital start of dapagliflozin, % patients on β-blockers, and the dosage of loop diuretics independently predicted the reduction in loop diuretic dosage. Even in analyses excluding patients who initiated dapagliflozin during hospitalization, loop diuretic dosage independently predicted loop diuretic reduction in multivariate analysis. The receiver operating characteristic curve for predicting reduced loop diuretic showed that the cut-off value for loop diuretic at the time of administration of dapagliflozin was 20 mg/day of oral furosemide equivalent. Conclusions: The dosage of loop diuretic used when dapagliflozin was started is a factor that predicts a subsequent reduction in the dose of loop diuretics.
- Open Access
- 7 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1074
Heart Rate Reduction and the Prognosis of Heart Failure Focused on Ivabradine
Cardioprotective medications referred to as the fantastic four are used to treat heart failure (HF). Additionally, ivabradine can also be used if the heart rate (HR) is elevated. An elevated HR is a prognostic factor in HF patients, as well as in the general population. In both HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), an elevated HR is associated with all-cause mortality, whereas cardiovascular death is only associated with the former. In addition, previous clinical trials revealed that ivabradine was useful only in HFrEF but not in HFpEF. Therefore, ivabradine is indicated for patients only with HFrEF. Moreover, ivabradine increases the stroke volume by ensuring an effective diastolic time as a result of the decreased HR. Including this effect, the introduction of ivabradine allowed for the discontinuation of dobutamine infusion used in HF patients and the uptitration of β-blockers in other reports. Additionally, ivabradine improves exercise tolerance and the subjective symptoms of HF. However, the effects of ivabradine on exercise tolerance remain poorly understood, and prospective clinical trials are underway. While these beneficial effects have been reported, side effects such as photopsia and atrial fibrillation have also been reported. It is important to use ivabradine appropriately in conjunction with standard HF treatment, including quadruple therapy.
- 7 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1074
Open AccessHeart Rate Reduction and the Prognosis of Heart Failure Focused on Ivabradine
Cardioprotective medications referred to as the fantastic four are used to treat heart failure (HF). Additionally, ivabradine can also be used if the heart rate (HR) is elevated. An elevated HR is a prognostic factor in HF patients, as well as in the general population. In both HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), an elevated HR is associated with all-cause mortality, whereas cardiovascular death is only associated with the former. In addition, previous clinical trials revealed that ivabradine was useful only in HFrEF but not in HFpEF. Therefore, ivabradine is indicated for patients only with HFrEF. Moreover, ivabradine increases the stroke volume by ensuring an effective diastolic time as a result of the decreased HR. Including this effect, the introduction of ivabradine allowed for the discontinuation of dobutamine infusion used in HF patients and the uptitration of β-blockers in other reports. Additionally, ivabradine improves exercise tolerance and the subjective symptoms of HF. However, the effects of ivabradine on exercise tolerance remain poorly understood, and prospective clinical trials are underway. While these beneficial effects have been reported, side effects such as photopsia and atrial fibrillation have also been reported. It is important to use ivabradine appropriately in conjunction with standard HF treatment, including quadruple therapy.
- Open Access
- 26 July 2024
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 19 (Suppl 2) , 4
Actual Condition of Transthyretin Amyloid Cardiac Amyloidosis: Single Centre Experience
- 26 July 2024
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 19 (Suppl 2) , 4
Open AccessActual Condition of Transthyretin Amyloid Cardiac Amyloidosis: Single Centre Experience
- Open Access
- 6 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2719
Role of Vascular Function in the Prognosis of Heart Failure Patients
Background: Blood vessels have the Windkessel effect and are involved in blood circulation. The breakdown of this mechanism is also involved in the pathogenesis of heart failure (HF); however, the relationship between vascular dysfunction and HF prognosis is not fully understood. Methods: We evaluated 214 patients hospitalized for HF at our institution who underwent a cardio–ankle vascular index (CAVI), which evaluates vascular function, between January 2012 and July 2018. To investigate factors (including CAVI) associated with major adverse cardiac events (MACE) during 1 year after patients with HF were discharged, we evaluated clinical profiles, blood tests, chest X-P, 12-lead electrocardiography, and transthoracic echocardiographic findings. MACE was defined as cardiovascular death or readmission for HF. Results: The severity of HF between the MACE and non-MACE was not significantly different. Previous HF and chronic kidney disease were significantly more common in the MACE group. CAVI and % mean atrial pressure in the MACE group were statistically higher than those in the non-MACE group. The cardiac shadow as shown by chest X-P and left ventricular size in the MACE group were significantly bigger, and HF preserved ejection fraction (EF) (EF > 50%) was significantly more common in the MACE group. In multivariate analysis, CAVI was an independent predictive factor for the occurrence of MACE (model 1; hazard ratio (HR): 1.33, 95% confidence interval (CI): 1.05–1.68, p = 0.018; model 2; HR: 1.31, 95% CI: 1.07–1.60, p = 0.009). Conclusions: Because high CAVI is associated with poor prognosis of HF, these patients require more careful treatment.
- 6 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2719
Open AccessRole of Vascular Function in the Prognosis of Heart Failure Patients
Background: Blood vessels have the Windkessel effect and are involved in blood circulation. The breakdown of this mechanism is also involved in the pathogenesis of heart failure (HF); however, the relationship between vascular dysfunction and HF prognosis is not fully understood. Methods: We evaluated 214 patients hospitalized for HF at our institution who underwent a cardio–ankle vascular index (CAVI), which evaluates vascular function, between January 2012 and July 2018. To investigate factors (including CAVI) associated with major adverse cardiac events (MACE) during 1 year after patients with HF were discharged, we evaluated clinical profiles, blood tests, chest X-P, 12-lead electrocardiography, and transthoracic echocardiographic findings. MACE was defined as cardiovascular death or readmission for HF. Results: The severity of HF between the MACE and non-MACE was not significantly different. Previous HF and chronic kidney disease were significantly more common in the MACE group. CAVI and % mean atrial pressure in the MACE group were statistically higher than those in the non-MACE group. The cardiac shadow as shown by chest X-P and left ventricular size in the MACE group were significantly bigger, and HF preserved ejection fraction (EF) (EF > 50%) was significantly more common in the MACE group. In multivariate analysis, CAVI was an independent predictive factor for the occurrence of MACE (model 1; hazard ratio (HR): 1.33, 95% confidence interval (CI): 1.05–1.68, p = 0.018; model 2; HR: 1.31, 95% CI: 1.07–1.60, p = 0.009). Conclusions: Because high CAVI is associated with poor prognosis of HF, these patients require more careful treatment.
- Open Access
- 1 January 2024
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (1) , 11-15
The Prevention of the New Onset of Heart Failure in Hypertensive Patients
In 2014, Japan was estimated to have approximately 27 million patients with hypertension (HT), and the ultimate goal of treatment is to prevent complications of HT, including heart failure (HF). The major structural changes in the heart that cause HF are left ventricular (LV) hypertrophy (LVH) and the resulting LV diastolic dysfunction. However, in patients with HT with well-controlled blood pressure (BP), whether they are in HF stage A (only HT) or B (with organic heart disease) is often unclear. It has been reported that strict BP control suppresses LVH, and the improvement of LVH leads to the suppression of cardiovascular complications. Thus, detecting HF stage B HT and providing appropriate treatment lead to the suppression of HF onset. This review focuses on the detection and treatment of organic heart disease in HT.
- 1 January 2024
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (1) , 11-15
Open AccessThe Prevention of the New Onset of Heart Failure in Hypertensive Patients
In 2014, Japan was estimated to have approximately 27 million patients with hypertension (HT), and the ultimate goal of treatment is to prevent complications of HT, including heart failure (HF). The major structural changes in the heart that cause HF are left ventricular (LV) hypertrophy (LVH) and the resulting LV diastolic dysfunction. However, in patients with HT with well-controlled blood pressure (BP), whether they are in HF stage A (only HT) or B (with organic heart disease) is often unclear. It has been reported that strict BP control suppresses LVH, and the improvement of LVH leads to the suppression of cardiovascular complications. Thus, detecting HF stage B HT and providing appropriate treatment lead to the suppression of HF onset. This review focuses on the detection and treatment of organic heart disease in HT.
- Open Access
- 1 December 2023
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 15 (10-11) , 456-460
Cardiac Amyloidosis Patient With Cardiac Conduction Disturbances
Transthyretin cardiac amyloidosis (ATTR-CA) has recently been diagnosed more because of advances in diagnostic techniques, such as 99mTc-labeled pyrophosphate (99mTc-PYP) scintigraphy. ATTR-CA remains poorly diagnosed by many physicians, except for cardiologists and neurologists, and by patients. In this manuscript, we present a patient who was recommended to undergo a close examination but developed cardiac conduction disturbances and defects due to delays in the examination and treatment initiation. The patient was a 72-year-old Japanese man treated for hypertension at our hospital for approximately 30 years. The patient was diagnosed with left ventricular hypertrophy at 62 years old and hospitalized for heart failure at 68 years old. ATTR-CA was suspected by 99mTc-PYP scintigraphy performed at 70 years old, and a skin biopsy was performed. However, the skin biopsy did not confirm the diagnosis, and myocardial biopsy was recommended, which was declined by the patient. He finally consented to myocardial biopsy 2 years later, leading to the diagnosis of ATTR-CA at 72 years old. However, the patient had atrial fibrillation and a complete atrioventricular block. If ATTR-CA were widely recognized and understood, it might have been diagnosed and treated before the cardiac conduction disturbances appeared. It is essential to have an understanding and appropriate examinations for ATTR-CA based on sufficient explanation and consent. J Clin Med Res. 2023;15(10-11):456-460 doi: https://doi.org/10.14740/jocmr5051
- 1 December 2023
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 15 (10-11) , 456-460
Open AccessCardiac Amyloidosis Patient With Cardiac Conduction Disturbances
Transthyretin cardiac amyloidosis (ATTR-CA) has recently been diagnosed more because of advances in diagnostic techniques, such as 99mTc-labeled pyrophosphate (99mTc-PYP) scintigraphy. ATTR-CA remains poorly diagnosed by many physicians, except for cardiologists and neurologists, and by patients. In this manuscript, we present a patient who was recommended to undergo a close examination but developed cardiac conduction disturbances and defects due to delays in the examination and treatment initiation. The patient was a 72-year-old Japanese man treated for hypertension at our hospital for approximately 30 years. The patient was diagnosed with left ventricular hypertrophy at 62 years old and hospitalized for heart failure at 68 years old. ATTR-CA was suspected by 99mTc-PYP scintigraphy performed at 70 years old, and a skin biopsy was performed. However, the skin biopsy did not confirm the diagnosis, and myocardial biopsy was recommended, which was declined by the patient. He finally consented to myocardial biopsy 2 years later, leading to the diagnosis of ATTR-CA at 72 years old. However, the patient had atrial fibrillation and a complete atrioventricular block. If ATTR-CA were widely recognized and understood, it might have been diagnosed and treated before the cardiac conduction disturbances appeared. It is essential to have an understanding and appropriate examinations for ATTR-CA based on sufficient explanation and consent. J Clin Med Res. 2023;15(10-11):456-460 doi: https://doi.org/10.14740/jocmr5051
- Open Access
- 30 August 2023
- Published by Wiley in Clinical Cardiology
- Vol. 46 (12) , 1495-1503
Importance of anemia in heart failure over blood pressure variability
BackgroundThe evaluation of arteriosclerosis (vascular function) is important when treating heart failure (HF). Vascular dysfunction is associated with anemia through renal function and endothelial nitric oxide synthase. Additionally, blood pressure (BP) variability (BPV) caused by vascular dysfunction is also associated with HF prognosis. However, how anemia and BPV may affect HF prognosis is unclear.MethodsBetween January 2012 and July 2018, 214 patients with HF were hospitalized. The cardio-ankle vascular index (CAVI) as an index of arteriosclerosis of these patients was measured. The patients were divided into the elevated and preserved CAVI groups. We investigated the factors related to major adverse cardiovascular events (MACEs) as cardiovascular death or rehospitalization within 1 year after discharge.ResultsIn the elevated CAVI group, significant differences in body mass index (BMI), BPV, left ventricular dimension, and hemoglobin levels were observed between patients with and without MACEs. In the preserved CAVI group, significant differences in BMI, diastolic/mean BP, and hemoglobin levels were observed between those with and without MACEs. The multivariate analysis showed an independent association between hemoglobin levels and MACE occurrence in both the elevated and preserved CAVI groups (elevated CAVI group: hazard ratio [HR] = 0.800, p = .045 [model 1], HR = 0.802, p = .035 [model 2]; preserved CAVI group: HR = 0.783, p = .049 [model 1], HR = 0.752, p = .023 [model 2], and HR = 0.754, p = .024 [model 3]).ConclusionsAnemia was independently associated with HF prognosis with or without arteriosclerosis. In both the elevated (A) and preserved (B) cardio-ankle vascular index (CAVI) groups, patients with low Hb levels had more major adverse cardiovascular events (MACEs) 1 year after discharge of acute decompensated heart failure (grouping according to the median Hb level). The multivariate analysis showed an independent association between hemoglobin levels and MACE occurrence in both the elevated and preserved CAVI groups (C; elevated CAVI group: hazard ratio [HR] = 0.800, p = .045 [model 1], HR = 0.802, p = .035 [model 2]: D; preserved CAVI group: HR = 0.783, p = .049 [model 1], HR = 0.752, p = .023 [model 2], and HR = 0.754, p = .024 [model 3]).image
- 30 August 2023
- Published by Wiley in Clinical Cardiology
- Vol. 46 (12) , 1495-1503
Open AccessImportance of anemia in heart failure over blood pressure variability
BackgroundThe evaluation of arteriosclerosis (vascular function) is important when treating heart failure (HF). Vascular dysfunction is associated with anemia through renal function and endothelial nitric oxide synthase. Additionally, blood pressure (BP) variability (BPV) caused by vascular dysfunction is also associated with HF prognosis. However, how anemia and BPV may affect HF prognosis is unclear.MethodsBetween January 2012 and July 2018, 214 patients with HF were hospitalized. The cardio-ankle vascular index (CAVI) as an index of arteriosclerosis of these patients was measured. The patients were divided into the elevated and preserved CAVI groups. We investigated the factors related to major adverse cardiovascular events (MACEs) as cardiovascular death or rehospitalization within 1 year after discharge.ResultsIn the elevated CAVI group, significant differences in body mass index (BMI), BPV, left ventricular dimension, and hemoglobin levels were observed between patients with and without MACEs. In the preserved CAVI group, significant differences in BMI, diastolic/mean BP, and hemoglobin levels were observed between those with and without MACEs. The multivariate analysis showed an independent association between hemoglobin levels and MACE occurrence in both the elevated and preserved CAVI groups (elevated CAVI group: hazard ratio [HR] = 0.800, p = .045 [model 1], HR = 0.802, p = .035 [model 2]; preserved CAVI group: HR = 0.783, p = .049 [model 1], HR = 0.752, p = .023 [model 2], and HR = 0.754, p = .024 [model 3]).ConclusionsAnemia was independently associated with HF prognosis with or without arteriosclerosis. In both the elevated (A) and preserved (B) cardio-ankle vascular index (CAVI) groups, patients with low Hb levels had more major adverse cardiovascular events (MACEs) 1 year after discharge of acute decompensated heart failure (grouping according to the median Hb level). The multivariate analysis showed an independent association between hemoglobin levels and MACE occurrence in both the elevated and preserved CAVI groups (C; elevated CAVI group: hazard ratio [HR] = 0.800, p = .045 [model 1], HR = 0.802, p = .035 [model 2]: D; preserved CAVI group: HR = 0.783, p = .049 [model 1], HR = 0.752, p = .023 [model 2], and HR = 0.754, p = .024 [model 3]).image